Condition

GLP-1 clinical trials and research

• 15Clinical trials
• 48NIH research projects
• 7Countries

Newest GLP-1 clinical trials

All recruiting trials (15)

• Ubiquinol to See if It Reduces Fatigue for Adults Using GLP-1 Weight-Loss Meds

  A daily ubiquinol supplement is tested to see if it lowers fatigue and helps keep muscle strength in adults taking GLP-1 weight-loss medicines.

  Recruiting StudySetGo · Glasgow · NCT07789106

• Discontinuation timing of GLP-1 receptor agonists before colonoscopy

  This study tests whether stopping GLP-1 receptor agonists for either 0 or 7 days before colonoscopy affects bowel prep quality and the need for a repeat procedure in adults undergoing colonoscopy.

  Recruiting Fu Jen Catholic University Hospital · New Taipei, Taiwan · NCT07736963

• Should GLP-1 receptor agonists be stopped a week before an endoscopy?

  A one-week pause of long-acting GLP-1 receptor agonists is being tested to see if it improves gastric prep quality and reduces the need for repeat endoscopy in adults undergoing EGD.

  Recruiting Phase 3 Fu Jen Catholic University Hospital · New Taipei City, Taiwan · NCT07736911

• GLP-1 receptor agonists and dry eye in adults with type 2 diabetes and obesity

  This study tests whether GLP-1 receptor agonists affect dry eye disease in adults with type 2 diabetes and obesity.

  Recruiting Attikon Hospital · Athens · NCT07605572

• Lifestyle change program with GLP-1 medication users

  This trial tests whether the Noom digital lifestyle program helps adults on GLP-1 medications improve eating, activity, and weight-related health.

  Recruiting University of Massachusetts, Worcester · Worcester, Massachusetts · NCT07481305

• A nutritional supplement to fill nutrient gaps and support gut health for people taking GLP-1 medications.

  This study will test whether a daily nutritional supplement can reduce nutrient gaps and improve the gut microbiome in adults who are using GLP-1 receptor agonist medications.

  Recruiting Athletic Greens International · Santa Monica, California · NCT07437911

• Semaglutide's effects on heart and muscle mass

  This project will use MRI scans and strength tests over 12 months to see if semaglutide changes body and heart muscle in adults starting the medication.

  Recruiting University of Alberta · Edmonton, Alberta · NCT07272837

• Effects of GLP-1 and GIP/GLP-1 medications on diet, metabolism, and behavior in adults with excess weight

  This project will test whether GLP-1 and GIP/GLP-1 medications change eating habits, weight, metabolism, and related behaviors in adults with overweight or obesity.

  Recruiting Medical University of Warsaw · Warsaw, Warszawa · NCT07270497

• Personalized weight-loss medication plan for adults with bipolar disorder

  This pilot tests whether matching FDA-approved weight-loss medicines to specific obesity types helps adults aged 18–65 with bipolar disorder lose weight.

  Recruiting Phase 4 Mayo Clinic · Rochester, Minnesota · NCT07213466

• How GLP-1 and GIP medications affect colonoscopy bowel cleansing

  This test will see if taking GLP‑1 or GIP medications affects bowel cleansing for adults getting an outpatient colonoscopy.

  Recruiting at 3 sites Phase 4 The Cleveland Clinic · Cleveland, Florida and 2 other locations · NCT07127354

• Keeping weight off after stopping GLP-1s using metformin with or without rapamycin or low‑dose naltrexone

  This trial will test whether metformin alone or combined with low‑dose rapamycin or low‑dose naltrexone helps adults 40–85 maintain weight loss after they stop GLP‑1 medications.

  Recruiting Phase 2/3 AgelessRx · Chicago, Illinois · NCT07092618

• Behavioral therapy plus GLP-1 medicines for binge eating and weight in people with obesity

  This project will try adding GLP-1 medications to a lifestyle program with CBT-E to see if they reduce binge eating and help adults with obesity lose weight and cope better.

  Recruiting Haukeland University Hospital · Bergen, Vestland · NCT07042672

• Bone health in 12–21-year-olds starting GLP-1 weight medicines

  This study will test whether starting GLP-1 receptor agonist medicines versus lifestyle management changes bone health over 24 months in 12–21-year-olds with obesity.

  Recruiting Phase 2 University of Virginia · Charlottesville, Virginia · NCT06903923

• Tirzepatide effects on muscle and blood-vessel health in older adults with obesity

  This trial will try tirzepatide for six months in adults 50 and older with obesity but without diabetes to see if it changes muscle mass, strength, and blood vessel health.

  Recruiting Phase 2 The University of Texas Health Science Center at San Antonio · San Antonio, Texas · NCT06811324

• Gastric ablation therapy for weight management after stopping GLP-1 medications

  This study tests if a procedure called gastric ablation can help adults keep off weight they lost with GLP-1 medications after they stop taking them.

  Recruiting True You Weight Loss · Cary, North Carolina and 1 other locations · NCT06734312

NIH-funded research (newest 40 of 48)

Early-stage science funded by the US National Institutes of Health. Most of these projects don't enroll patients, but they show what is being worked on.

• Understanding how GLP-1 drugs affect energy use in brittle diabetes

  This grant looks at how GLP-1 receptor drugs change how the body handles sugar and fats, beyond lowering blood sugar or appetite, to help people with brittle diabetes.

  NIH research Harvard University D/b/a Harvard School of Public Health · Boston, United States · NIH-11599303

• GLP-1 receptor drugs and heart-brain health in diabetes and Alzheimer’s risk

  A Duke-led study will explore how GLP-1 receptor medicines and exercise affect brain and heart health in models prone to diabetes and Alzheimer’s risk.

  NIH research Duke University · Durham, United States · NIH-11536555

• GLP-1 medicines to improve heart, kidney, and metabolic health for people with HIV and type 2 diabetes

  A real-world study will look at how GLP-1 receptor agonists affect heart and kidney health and lifetime costs for people living with HIV and type 2 diabetes.

  NIH research Boston University Medical Campus · Boston, United States · NIH-11470780

• Lifestyle plan to protect muscle and heart health for adults with obesity using GLP-1 medications

  A real-world trial tests a combined nutrition and resistance-training program versus standard care for adults starting GLP-1 weight loss drugs to preserve lean mass and cardiovascular health.

  NIH research University of Florida · Gainesville, United States · NIH-11452740

• Pre-pregnancy GLP-1 Medication Use and Stopping It: Effects on Blood Sugar and Pregnancy Outcomes

  This project looks at how using GLP-1–based weight loss medicine before pregnancy and stopping it before trying to conceive affects blood sugar and pregnancy health.

  NIH research University of Rochester · Rochester, United States · NIH-11438182

• Ways to keep weight off after stopping GLP-1 weight-loss meds

  This project tests simple strategies to help adults who have obesity keep weight off after stopping high-dose GLP-1 medicines.

  NIH research Massachusetts General Hospital · Boston, United States · NIH-11428011

• GLOW-UPS: long-acting vs daily buprenorphine for people leaving prison

  A large study will compare long-acting injectable buprenorphine to daily oral buprenorphine for adults with opioid use disorder who are about to leave prison, to see which keeps people adherent and safe after release.

  NIH research New York University School of Medicine · New York, United States · NIH-11415917

• Integrated treatment for people with both opioid and alcohol use disorders using GLP-1 medicines and standard therapies

  A real-world study of how combining GLP-1 receptor agonists with usual opioid and alcohol treatments works for people who have both disorders.

  NIH research Loyola University Chicago · Maywood, United States · NIH-11413630

• GLP-1 receptor agonists for alcohol use disorder in real-world care

  This project looks at how GLP-1 receptor agonists used for diabetes and heart health perform in real-world adults with alcohol use disorder.

  NIH research Emory University · Atlanta, United States · NIH-11413626

• Low-cost, heat-stable GLP-1 and GIP receptor agonists produced in maize for diabetes and obesity

  This project aims to make affordable, heat-stable versions of diabetes and obesity medicines using corn plants.

  NIH research Applied Biotechnology Institute · San Luis Obispo, United States · NIH-11405484

• GLP-1 drugs to reduce alcohol use and heart risk in people with HIV

  A Vanderbilt team is testing whether GLP-1 receptor agonists can help people with HIV drink less, quit smoking, and cut heart disease risk.

  NIH research Vanderbilt University Medical Center · Nashville, United States · NIH-11395348

• GLP-1, Alcohol, and Gut Microbes in HIV

  This grant explores how the body's own GLP-1 system, alcohol use, and gut microbes may influence heart health in people living with HIV.

  NIH research Vanderbilt University Medical Center · Nashville, United States · NIH-11395333

• Hydrogen sulfide and GLP-1 combo therapy for HFpEF

  A patient-friendly look at a new treatment approach that combines hydrogen sulfide donors with GLP-1 agonists to help people with HFpEF feel better and stay out of the hospital.

  NIH research Cedars-Sinai Medical Center · Los Angeles, United States · NIH-11394533

• Understanding how GLP-1 receptor medicines affect weight and metabolic memory

  This NIH grant plans to study why people regain weight after stopping GLP-1 receptor agonists and how their bodies keep metabolic memories of treatment, with a focus on adults living with obesity.

  NIH research University of Texas Hlth Sci Ctr Houston · Houston, United States · NIH-11391979

• GLP-1/GIP receptor activating therapy to help adults quit smoking and lose weight

  A large study will test a GLP-1/GIP receptor agonist to help adults with atherosclerotic cardiovascular disease quit smoking and manage weight.

  NIH research University of Southern California · Los Angeles, UNITED STATES · NIH-11373082

• Obesity and GLP-1 treatment in young people with type 1 diabetes

  A study in teens and young adults with type 1 diabetes and obesity will look at how a GLP-1–based obesity medicine affects body fat distribution, insulin resistance, and lipids.

  NIH research Yale University · New Haven, United States · NIH-11370619

• GLP-1 receptor medicines and brain changes in teen and adult obesity

  This study tests how GLP-1 receptor medicines affect brain function and weight in adolescents with obesity compared to adults.

  NIH research University of Colorado Denver · Aurora, UNITED STATES · NIH-11363964

• GLP-1 receptor agonists in children: safety, benefits, and long-term impact

  A pediatric-focused study will track how GLP-1 receptor agonists affect kids aged 10–18 with obesity or type 2 diabetes over time, looking at safety and real-world outcomes.

  NIH research Indiana University Indianapolis · Indianapolis, United States · NIH-11357531

• A scalable plan to help people keep weight off after stopping obesity medications

  A new pilot program helps adults keep weight off after stopping GLP-1 medications or other anti-obesity drugs by using structured eating, activity, and mind-based practices.

  NIH research University of Alabama at Birmingham · Birmingham, United States · NIH-11342005

• GLP-1 medications to help prevent and treat opioid use disorder

  This project looks at whether GLP-1 receptor agonists, already used for diabetes and obesity, can help people with opioid use disorder.

  NIH research Mayo Clinic Rochester · Rochester, United States · NIH-11334041

• How brain GLP-1 controls appetite and body weight

  This project looks at how a brain hormone called GLP-1 controls hunger and body weight to help people with obesity and type 2 diabetes.

  NIH research Rutgers Biomedical and Health Sciences · Newark, UNITED STATES · NIH-11330270

• Bone health in teens taking GLP-1 weight-loss medicines

  This project looks at whether GLP-1 weight-loss medicines harm or protect bone growth in adolescents who lose weight.

  NIH research University of Virginia · Charlottesville, United States · NIH-11326203

• GLP-1 producing engineered probiotics to help manage metabolic diseases

  A research project aims to create probiotic bacteria that constantly deliver GLP-1 to help people with type 2 diabetes and obesity manage their condition.

  NIH research Medosome Biotec, LLC · Alachua, UNITED STATES · NIH-11314389

• Islet GLP-1 and hormone control in adults with brittle or type 2 diabetes

  This research looks at how the body's own GLP-1 hormone affects how the pancreas handles insulin and glucose in adults with brittle diabetes and related conditions.

  NIH research Mayo Clinic Rochester · Rochester, United States · NIH-11296888

• Comparing bariatric (weight‑loss) surgery with GLP‑1 and SGLT‑2 diabetes medicines for people with obesity and type 2 diabetes

  This project compares long-term benefits and safety of weight‑loss surgery versus GLP‑1 and SGLT‑2 diabetes medicines for adults who have obesity and type 2 diabetes.

  NIH research Kaiser Foundation Research Institute · Oakland, UNITED STATES · NIH-11290742

• GLP-1 drugs and muscle health in older adults

  This study looks at how GLP-1 receptor agonists used by older adults might affect muscle mass, strength, and function over six months.

  NIH research Arizona State University-Tempe Campus · Scottsdale, United States · NIH-11288766

• How GLP-1 medications change drinking and the way alcohol feels

  This project will test whether GLP-1 medicines (like Ozempic, Wegovy, Mounjaro) lower drinking and change how alcohol feels for people with alcohol use disorder.

  NIH research Univ of North Carolina Chapel Hill · Chapel Hill, United States · NIH-11241674

• n-3 fats and GLP-1 drugs to help AUD and alcoholic liver disease

  Aims to test whether omega-3 fats plus a GLP-1 drug can reduce drinking and liver damage in people at risk for alcohol use disorder and alcoholic liver disease.

  NIH research University of Louisville · Louisville, United States · NIH-11232903

• Integrated medication approaches for people with both opioid and alcohol use disorders

  This project looks at how combining common addiction medicines and GLP-1 receptor agonists works for people who have both opioid and alcohol use problems using large-scale medical records.

  NIH research Loyola University Chicago · Maywood, United States · NIH-11196080

• Targeting the GLP-1 pathway to reduce unhealthy food and alcohol cravings during withdrawal

  This project looks at whether medicines that act on the GLP-1 system can help people recovering from alcohol use disorder reduce binge eating and alcohol craving.

  NIH research Drexel University · Philadelphia, United States · NIH-11165947

• Understanding and treating obesity in young people with type 1 diabetes

  This research explores how a medication for obesity, called a GLP-1 analogue, helps young people with type 1 diabetes manage their weight and reduce heart-related health risks.

  NIH research Yale University · New Haven, United States · NIH-11126759

• Improving blood pressure control in diabetes by timing GLP-1 medications

  This work explores how the timing of certain diabetes medications might help people with type 2 diabetes better manage their blood pressure, especially if it doesn't drop normally at night.

  NIH research University of Kentucky · Lexington, United States · NIH-11099739

• Understanding how brain signals control energy balance and food intake

  This study is looking at how a hormone called GLP-1 in the brain helps control hunger and energy use, with the hope of finding new ways to help people manage obesity.

  NIH research Rutgers Biomedical and Health Sciences · Newark, UNITED STATES · NIH-11092860

• Genes and GLP-1 treatment response in Mexican‑American adults with prediabetes

  This project checks if genetic differences change how Mexican‑American adults with prediabetes respond to GLP‑1 therapies.

  NIH research University of Texas Hlth Sci Ctr Houston · Houston, United States · NIH-11086079

• Using a GLP-1 Agonist to Help Treat Opioid Addiction

  This study is looking at whether a new medication can help people with opioid addiction feel less cravings and reduce the chances of going back to using opioids, based on encouraging results seen in animals.

  NIH research Pennsylvania State Univ Hershey Med Ctr · Hershey, United States · NIH-11077300

• Creating a needle-free patch to deliver diabetes medication.

  This study is testing a new, easy-to-use patch that delivers a diabetes medication without needles, making it less scary for people with Type 2 diabetes to stick to their treatment.

  NIH research Vaxess Technologies, INC. · Cambridge, United States · NIH-11068410

• Effects of a medication on brain function and thinking skills in veterans with schizophrenia

  This study is looking at how a medication called a GLP-1 receptor agonist might help improve thinking and brain function in veterans with schizophrenia, using special imaging to see how it affects their brain activity.

  NIH research VA Eastern Colorado Health Care System · Aurora, UNITED STATES · NIH-11054481

• Comparing the effectiveness and safety of surgery and medications for obesity and type 2 diabetes

  This study is looking at how well metabolic surgery works compared to certain medications for treating obesity and type 2 diabetes, so that patients and doctors can better understand the best options for managing these conditions, especially for those who might not always get the best care.

  NIH research Kaiser Foundation Research Institute · Oakland, UNITED STATES · NIH-11051211

• Understanding how a natural hormone affects the pancreas in diabetes

  This project explores how a natural hormone called GLP-1, made in your body, helps your pancreas manage blood sugar, especially for people with prediabetes and type 2 diabetes.

  NIH research Mayo Clinic Rochester · Rochester, United States · NIH-11034407

• Exploring treatments for patients with both opioid and alcohol use disorders

  This study is looking at how different treatment methods can help people who are dealing with both opioid and alcohol problems, to see which options work best for improving their overall health and recovery.

  NIH research Loyola University Chicago · Maywood, United States · NIH-11001407

Related topics

Quick answers

How many GLP-1 clinical trials are recruiting right now?

15, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.

Where are these trials running?

In 7 countries. The most sites are in United States (8 trials), Taiwan (2 trials), United Kingdom (1 trial), Norway (1 trial), Greece (1 trial). Each study page lists its sites and which ones are recruiting.

What phases are they in?

Phase 4: 2, Phase 2: 2, Phase 2/3: 1, Phase 3: 1. Trials with no phase listed are usually device, behavioural or observational studies.

How do I join one?

Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.

Find the studies that fit you

A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.

Describe your situation →